Skip to Content

A Favorable Safety Profile of IL-23 p19 Inhibitors for Psoriasis

According to dermatologist Andy Blauvelt, the safety of biologics for dermatological diseases such as psoriasis is a significant issue. And he is often asked, ‘’What is the safest one to use?”. New results presented in this MEDtalk indicate a safe and effective profile of IL-23 p19 inhibitors for treating patients with moderate-to-severe plaque psoriasis.

Andy Blauvelt

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top